FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19

The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with COVID-19.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news